Leader in the development of permanent seed brachytherapy in the treatment of cancer.
Press Releases
NEWS RELEASE for February 7, 2008
| Contact | Allen & Caron Michael Mason (investors) Brian Kennedy (media) 212 691 8087 michaelm@allencaron.com brian@allencaron.com |
Lori Woods, VP 206 604 6400 lwoods@isoray.com |
Richland, WA (February 7, 2008) … IsoRay Inc (Amex: ISR), a leading-edge developer and manufacturer of brachytherapy seeds for the treatment of prostate cancer and other solid tumors, announced today that 23 physicians attended its recent over-subscribed Proxcelan Cesium-131 Prostate Brachytherapy Educational Workshop at the Chicago Prostate Cancer Center (CPCC). This workshop was the first of three to take place at the CPCC, a center dedicated to treating men with prostate cancer.
“As part of our strategic market penetration plan we intend to continue these programs with the next CPCC course scheduled for May 29 and 30, 2008,” said Roger Girard, President and CEO. “IsoRay is dedicated to a strategy of ongoing educational initiatives including using the latest live webcast technology in partnership with our Medical Director, Steve Kurtzman, MD. IsoRay will have the technology to schedule these live webcasts reaching physicians in groups with large screens, or individual physicians and their staffs with PCs. We will be scheduling these live webcasts throughout the rest of 2008 and beyond for use in all of our markets.”
The workshop was held at Chicago Prostate Cancer Center (CPCC) with Brian Moran, MD, founder and principal of CPCC leading the two-day course. Guest speaker William Bice, PhD presented the latest results from the IsoRay Monotherapy trial. The objective of these courses was to educate providers on the unique characteristics of Proxcelan and how these differences translate into modified implant planning techniques. The feedback and responses from the attendees was overwhelmingly positive on the follow-up evaluations.
"It is a unique technology and it deserves unique instruction,” said Dr. Moran.
He added, “You need to understand Cesium, respect it and don’t be afraid to use it. Our outcomes at three years are excellent.”
PCC is one of the few centers in the United States dedicated solely to the treatment of prostate cancer using brachytherapy, and one of the busiest implant centers in the country with over 10,000 patient implants to date.
Founded in 1997, CPCC is a 35,000-square-foot, state-of-the-art facility located at 815 Pasquinelli Drive in Westmont, Illinois, a suburb of Chicago. For more information, visit www.prostateimplant.com.
# # #
About IsoRay IncIsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Proxcelan™ Cesium-131 brachytherapy seed, used to treat prostate and other cancers. The Proxcelan™ seed offers a significantly shorter half-life than the two other isotopes commonly used for brachytherapy, which results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of the longevity of common brachytherapy side effects (a)(b). IsoRay is based in Richland, Washington. More information is available about IsoRay at www.isoray.com.
a) Armpilia CI, Dale RG, Coles IP, et al. The Determination of Radiobiologically Optimized Half-lives for Radionuclides Used in Permanent Brachytherapy Implants. Int. J. Radiation Oncology Biol. Phys. 2003; 55 (2): 378-385.
(b) Prestidge B.R., Bice W.S., Jurkovic I., et al. Cesium-131 Permanent Prostate Brachytherapy: An Initial Report. Int. J. Radiation Oncology Biol. Phys. 2005; 63 (1): 5336-5337.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Proxcelan Cesium-131 seed, whether future workshops and physician training events will be scheduled and whether such events will result in favorable responses from physicians, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, and other risks detailed from time to time in IsoRay's reports filed with the SEC.